Financial opportunities for early stage biotech companies
This is a student paper from the 2009 final projects in the NIH Foundation for Advanced Education in the Sciences’ […]
Financial opportunities for early stage biotech companies Read Post »
This is a student paper from the 2009 final projects in the NIH Foundation for Advanced Education in the Sciences’ […]
Financial opportunities for early stage biotech companies Read Post »
John Avellanet, a frequent contributor to this blog, is giving a talk for my biotechnology management class at the NIH
An Overview of the Biopharmaceutical Landscape Ahead Read Post »
I will be opening the Business Matters for Scientists program at Johns Hopkins Carey School of Business on March 6th
Biotechnology Certificate Program at JHU's Carey School of Business Read Post »
I will be opening the Business Matters for Scientists program at Johns Hopkins Carey School of Business on March 6th
Biotechnology Certificate Program at JHU’s Carey School of Business Read Post »
After months of effort, I’m pleased to announce the launch of Biotech U, a biotechnology education resource featuring web-based lessons
Introducing Biotech-U: Web-based courses on biotechnology Read Post »
After an extended struggle Mark Emalfarb, the founder of Dyadic has regained control of the firm. He was originally ousted
Guest content from Sandy Graham, managing partner at Sequoyah Associates: Can you “see the field” of opportunity? Have your clearly
The science of biotechnology is tough. R&D can be unpredictable, and most products need regulatory approval before they can be
Dyadic founder fights to regain control of company Read Post »